Rh-endostatin [Endostar] Injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: Randomized, double-blind, placebo-controlled, multicentre study.

Trial Profile

Rh-endostatin [Endostar] Injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: Randomized, double-blind, placebo-controlled, multicentre study.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs Endostatin (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Sponsors Shandong Simcere Medgenn Bio-Pharmaceutical
  • Most Recent Events

    • 05 Jun 2012 Biomarker analysis presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 28 Apr 2011 Primary endpoint 'Progression-free-survival' has not been met, based on results published in the Journal of Thoracic Oncology.
    • 28 Apr 2011 Results published in the Journal of Thoracic Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top